TCGX Announces Oversubscribed $600 Million Asia Fund

Gunderson Dettmer represented TCGX in the formation of its oversubscribed $600 million Asia Life Sciences Fund I.

TCGX is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that improve the lives of patients. The fund will focus on investing in innovative biotechnology companies based in Asia and will expand TCGX’s ability to invest behind compelling science across the world while maintaining distinct regional investment strategies.

“Asia has become an increasingly important source of globally competitive biotechnology innovation,” said Dr. Chen Yu, Founder and Managing Partner of TCGX, in the announcement of the fund. “We believe there is a significant opportunity to partner with exceptional entrepreneurs and scientists across the region who are building companies capable of developing transformative medicines for patients worldwide. The Asia Fund gives us a dedicated platform to pursue these opportunities while leveraging the broader capabilities and network of TCGX.”

The Gunderson team included Andrew Thornborrow, Olga Zolotnik, Luke Charette, Amanda Chan, Bria Guitano, and Casey Stevens.